Drug-induced prolongation of the QT interval.

@article{Roden2004DruginducedPO,
  title={Drug-induced prolongation of the QT interval.},
  author={D. Roden},
  journal={The New England journal of medicine},
  year={2004},
  volume={350 10},
  pages={
          1013-22
        }
}
  • D. Roden
  • Published 2004
  • Medicine
  • The New England journal of medicine
The single most common cause of the withdrawal or restriction of the use of marketed drugs has been QT-interval prolongation associated with polymorphic ventricular tachycardia, or torsade de pointes, a condition that can be fatal. This review summarizes the current knowledge about molecular and clinical predictors of drug-induced QT-interval prolongation and torsade de pointes and discusses how new molecular predictors of drug action might be incorporated into drug-development programs and… Expand
Drug-induced QT prolongation: consequences and current dilemma.
TLDR
A case of extreme QT interval prolongation in association with drug therapy and the measures required to treat it is described. Expand
Drug-induced QT interval prolongation after ciprofloxacin administration in a patient receiving olanzapine.
TLDR
An elderly woman receiving a long-term medication with azathioprine, olanzapine and valsartan developed a marked QT interval prolongation after intravenous administration of ciprofloxacin. Expand
Drug-Induced Long QT Syndrome and Torsades de Pointes
TLDR
Current advances in the development of clinical decision support systems for management of this information and the ability to include the results of genomic testing in the electronic medical record are encouraging signs that this preventable adverse drug reaction may someday soon, in fact, be prevented. Expand
QT interval prolongation and torsade de pointes associated with indapamide.
TLDR
The case of an acquired long QT and torsade de pointes ventricular tachycardia in a woman with systemic lupus erythematosus and hypertension receiving prednisolone and indapamide, respectively, is described in the present report. Expand
Drugs and the QT interval - caveat doctor.
TLDR
During the past few years, many drugs have been removed from the market or required to include “black box” warnings on their labels because of the potential for QT-interval prolongation. Expand
Genetics of acquired long QT syndrome.
TLDR
The molecular and cellular mechanisms underlying this acquired or drug-induced form of long QT syndrome are summarized, approaches to the analysis of a role for DNA variants in the mediation of individual susceptibility are described, and it is proposed that these concepts may be generalizable to common acquired arrhythmias. Expand
Drug-induced QT interval prolongation: Do we know the risks?
TLDR
This review analyzes the drugs that prolong the QT interval, the risk factors that can enhance QT prolongation and the drug interactions that can increase these risks. Expand
[Proarrhythmic adverse effects of nonarrhythmic drugs].
TLDR
During drug prescription, it is necessary to monitor QTc with regular ECGs and end of drug administration followed by monitoring of the patient according to the individual risk for TdP. Expand
Magnitude of QT prolongation associated with a higher risk of Torsades de Pointes
TLDR
Values inferred from a population that predict a stronger potential for drug induced TdP are identified. Expand
QT interval prolongation associated with venlafaxine administration.
TLDR
A 60-year-old woman who admitted to the hospital due to hypertension and mild dyspnea having a prolonged QT interval (QTc: 582 ms) had a known history of depression treated with venlafaxine, and the QT intervals normalised a few days after cessation of the antidepressant agent. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 88 REFERENCES
Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care.
TLDR
Clinical data in 24 patients with the quinidine-associated long QT syndrome, 20 of whom had torsade de pointes, were reviewed, delineated several heretofore unreported or underemphasized features and estimated the risk as at least 1.5% per year. Expand
Evidence for a Cardiac Ion Channel Mutation Underlying Drug‐Induced QT Prolongation and Life‐Threatening Arrhythmias
TLDR
It is demonstrated that some cases of drug‐induced QT prolongation may depend on a genetic substrate, and molecular screening may allow identification among family members of gene carriers potentially at risk if treated with Ikr blockers. Expand
Torsade de pointes: the long-short initiating sequence and other clinical features: observations in 32 patients.
TLDR
A characteristic long-short ventricular cycle length as the initiating sequence was found in 41 of 44 episodes of torsade de pointes and it is suggested that this electrocardiographic characteristic will aid in both establishing the diagnosis and distinguishing it from other polymorphic forms of ventricular tachycardia. Expand
A common polymorphism associated with antibiotic-induced cardiac arrhythmia.
TLDR
It is concluded that allelic variants of MiRP1 contribute to a significant fraction of cases of drug-induced LQTS through multiple mechanisms and that common sequence variations that increase the risk of life-threatening drug reactions can be clinically silent before drug exposure. Expand
Exaggerated QT prolongation after cardioversion of atrial fibrillation.
TLDR
There was increased sensitivity to QT prolongation by this I(Kr)-specific blocker shortly after restoration of SR, and slower heart rates after cardioversion and QT dispersion during treatment appear to be important predictors of this response. Expand
Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes
  • D. Roden
  • Medicine
  • Pacing and clinical electrophysiology : PACE
  • 1998
TLDR
Progress toward understanding mechanisms underlying torsades de pointes and identifying patients at risk would go a long way to rationalizing therapy with currently available antiarrhythmic drugs and perhaps directing development of new agents. Expand
The Canine Purkinje Fiber: An In Vitro Model System for Acquired Long QT Syndrome and Drug-Induced Arrhythmogenesis
TLDR
This Purkinje fiber model detects six of seven drugs linked clinically to acquired long QT syndrome and torsade de pointes, and clears each of five drugs not associated with repolarization abnormalities (overall 92% accuracy), validating the utility of this Purkinjen fiber model in the preclinical evaluation of QT prolongation and proarrhythmic risk by noncardiac drugs. Expand
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs.
TLDR
It is strongly suggested that women are more prone than men to develop torsades de pointes during administration of cardiovascular drugs that prolong cardiac repolarization. Expand
Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias
TLDR
It is concluded that I Kr blocking potency can be readily assessed in either AT-1 cells or systems in which HERG is heterologously expressed, and not all drugs causing TdP are potent I Kr blockers, and I Kr block is not necessarily associated with Td P. Expand
Quinidine Syncope: Paroxysmal Ventricular Fibrillation Occurring during Treatment of Chronic Atrial Arrhythmias
TLDR
The purpose of this communication is to focus attention on syncopal attacks occurring during quinidine therapy and apparently related to paroxysms of ventricular flutter or fibrillation. Expand
...
1
2
3
4
5
...